EDNRA and chronic kidney disease: The ETAR antagonist atrocentan reduced doubling of the serum creatinine level, ESKD, or kidney death in 2,648 patients with type 2 diabetes and CKD by 35% (p = 0.0047) in the SONAR Trial (16).